Active immunization with immune checkpoint inhibitors-mimotope elicits strong *in vivo* anti-tumor effect against Her-2/neu-expressing tumors

Joshua Tobias1*, C. Battin1, A. De Sousa Linhares1, M. Lebens2, K. Baier1, K. Ambroz1, M. Drinic1, S. Högler3, A. Inic-kanada1, E. Garner-Spitzer1, M. Preusser1,4, L. Kenner3, M. Kundl1, C. C. Zielinski1,4, P. Steinberger1, U. Wiedermann1*

**Introduction and Aim**

Immunotherapy based on the application of monoclonal antibodies (mAbs) as immune checkpoint inhibitors (ICIs) has demonstrated remarkable clinical activity in various malignancies. The cost intensiveness as a possible limiting factor of such approach, however, may be overcome by direct immunization with mimotopes (B cell epitopes) of the corresponding ICIs. By establishing a platform, involving overlapping peptides spanning the extracellular domain of PD1, T cell-based cellular assay and a syngeneic mouse model with tumor expressing Her-2/neu, mimotopes of the anti-human PD1 mAb Nivolumab (as an example) and of anti-mouse PD1 mAb (for evaluating anti-tumor activity in vivo) were identified and characterized.

**Aim:** To generate ICIs mimotopes with strong capacity in inducing antibody response with anti-tumor activity.

---

**Summary and conclusion**

Our results show:
1. Identification of PD1-derived mimotopes
2. Immunization with PD1-derived mimotope induces antibodies with anti-tumor activity (passive immunization) comparable to the corresponding ICI.
3. Active immunization with PD1-derived mimotope induces anti-tumor activity in vivo with increased apoptotic and anti-proliferative effect in the tumors.
4. Active immunization with PD1-derived mimotope combined with the second generation of our anti-Her-2/neu vaccine (Her-Vaxx) increases the anti-tumor effect of the vaccine compared to each antigen alone.

Our results imply active immunization with mimotopes of ICIs as future treatment strategies with the corresponding ICIs, and their use either as monovalent vaccines or in combination with tumor specific antigens for enhancing the efficacy of the vaccinations against different malignancies.

---

1. Medical University of Vienna, Austria, 2. University of Gothenburg, Sweden, 3. University of Veterinary Medicine, Vienna, Austria 4. Vienna Cancer Center, Austria.

*Conflict of interests: MP, CCZ, PS and UW declare potential conflicts of interests. ** The study was supported by a research grant from Imugene (Australia) to the Medical University of Vienna.

**Contact:** joshua.tobias@meduniwien.ac.at, ursula.wiedermann@meduniwien.ac.at